Marker Therapeutics Current Deferred Revenue Over Time
| MRKR Stock | USD 3.52 0.08 2.33% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Marker Therapeutics Performance and Marker Therapeutics Correlation. Marker |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marker Therapeutics. If investors know Marker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marker Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.07) | Revenue Per Share 0.42 | Quarterly Revenue Growth 0.533 | Return On Assets (0.41) | Return On Equity (0.72) |
The market value of Marker Therapeutics is measured differently than its book value, which is the value of Marker that is recorded on the company's balance sheet. Investors also form their own opinion of Marker Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Marker Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marker Therapeutics' market value can be influenced by many factors that don't directly affect Marker Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Marker Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marker Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marker Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Marker Therapeutics and related stocks such as Lumos Pharma, Exicure, and Protagenic Therapeutics Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LUMO | 1.2 M | 84 K | 84 K | 84 K | 13 M | 892 K | 391 K | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 64.4 K | 61.2 K |
| XCUR | 8.3 M | 8.3 M | 8.3 M | 8.3 M | 8.3 M | 8.3 M | 8.3 M | 1 M | 21.9 M | 21.9 M | 8.3 M | 17.3 M | 17.3 M | 19.9 M | 12.5 M |
| PTIX | 152 K | (132) | (132) | (399) | (399) | (399) | (399) | (399) | (399) | (399) | (399) | (399) | (399) | (359) | (341) |
| PMVP | 92 K | 92 K | 92 K | 92 K | 92 K | 92 K | 92 K | 92 K | 92 K | 92 K | 92 K | 92 K | 92 K | 82.8 K | 73.6 K |
| BNOX | 72.9 K | 18.2 K | 37.4 K | 3.3 M | 75.4 K | 65.8 K | 19.5 K | (4.2 M) | 158.4 K | (4.1 M) | (130.8 K) | (110.1 K) | (114.4 K) | (796.8 K) | (756.9 K) |
| AGEN | 11.3 M | 1.5 M | 1.5 M | 1.7 M | 184.4 K | 3.8 M | 2.6 M | 4.5 M | 1.8 M | 29.2 M | 17.2 M | 12.4 M | 12.3 M | 18 K | 17.1 K |
| RNXT | 311 K | 311 K | 311 K | 311 K | 311 K | 311 K | 311 K | 311 K | 311 K | 311 K | 311 K | 311 K | 311 K | 279.9 K | 248.8 K |
| TPST | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 300.6 K | 267.2 K |
| IKNA | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.6 M | 17.1 M | 9.2 M | 1.0 | 0.95 |
| ACRV | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 69 K | 79.3 K | 74.2 K |
| ALEC | 19 M | 19 M | 19 M | 19 M | 19 M | 19 M | 19 M | 19 M | 34.9 M | 30.2 M | 23.9 M | 90.8 M | 48.2 M | 83 M | 51.8 M |
| AADI | (163.7 K) | (163.7 K) | (163.7 K) | (163.7 K) | (163.7 K) | (163.7 K) | (4.3 K) | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 21.2 M | 22.2 M |
| KROS | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 1.9 M | 4.4 M | 7.1 M | 17.3 M | 19.8 M | 20.8 M |
| AVTE | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 906.3 K | 805.6 K |
Marker Therapeutics and related stocks such as Lumos Pharma, Exicure, and Protagenic Therapeutics Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| Marker Therapeutics | MRKR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Texas; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.52
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.